Novartis AG Statistics
Total Valuation
Novartis AG has a market cap or net worth of $240.29 billion. The enterprise value is $262.68 billion.
| Market Cap | 240.29B |
| Enterprise Value | 262.68B |
Important Dates
The last earnings date was Tuesday, October 28, 2025, before market open.
| Earnings Date | Oct 28, 2025 |
| Ex-Dividend Date | Mar 12, 2025 |
Share Statistics
Novartis AG has 1.92 billion shares outstanding. The number of shares has decreased by -3.84% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 1.92B |
| Shares Change (YoY) | -3.84% |
| Shares Change (QoQ) | -1.02% |
| Owned by Insiders (%) | 0.11% |
| Owned by Institutions (%) | 37.35% |
| Float | 1.83B |
Valuation Ratios
The trailing PE ratio is 17.19 and the forward PE ratio is 13.68.
| PE Ratio | 17.19 |
| Forward PE | 13.68 |
| PS Ratio | 4.26 |
| Forward PS | 4.37 |
| PB Ratio | 5.37 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 12.27 |
| P/OCF Ratio | 11.40 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 10.54, with an EV/FCF ratio of 13.42.
| EV / Earnings | 18.25 |
| EV / Sales | 4.66 |
| EV / EBITDA | 10.54 |
| EV / EBIT | 12.84 |
| EV / FCF | 13.42 |
Financial Position
The company has a current ratio of 0.88, with a Debt / Equity ratio of 0.72.
| Current Ratio | 0.88 |
| Quick Ratio | 0.58 |
| Debt / Equity | 0.72 |
| Debt / EBITDA | 1.27 |
| Debt / FCF | 1.64 |
| Interest Coverage | 18.35 |
Financial Efficiency
Return on equity (ROE) is 32.62% and return on invested capital (ROIC) is 16.78%.
| Return on Equity (ROE) | 32.62% |
| Return on Assets (ROA) | 12.13% |
| Return on Invested Capital (ROIC) | 16.78% |
| Return on Capital Employed (ROCE) | 27.17% |
| Revenue Per Employee | $742,880 |
| Profits Per Employee | $189,674 |
| Employee Count | 75,883 |
| Asset Turnover | 0.53 |
| Inventory Turnover | 2.17 |
Taxes
In the past 12 months, Novartis AG has paid $2.04 billion in taxes.
| Income Tax | 2.04B |
| Effective Tax Rate | 12.40% |
Stock Price Statistics
The stock price has increased by +13.55% in the last 52 weeks. The beta is 0.57, so Novartis AG's price volatility has been lower than the market average.
| Beta (5Y) | 0.57 |
| 52-Week Price Change | +13.55% |
| 50-Day Moving Average | 127.30 |
| 200-Day Moving Average | 116.79 |
| Relative Strength Index (RSI) | 44.46 |
| Average Volume (20 Days) | 1,786,098 |
Short Selling Information
The latest short interest is 4.35 million, so 0.23% of the outstanding shares have been sold short.
| Short Interest | 4.35M |
| Short Previous Month | 4.27M |
| Short % of Shares Out | 0.23% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 2.85 |
Income Statement
In the last 12 months, Novartis AG had revenue of $56.37 billion and earned $14.39 billion in profits. Earnings per share was $7.30.
| Revenue | 56.37B |
| Gross Profit | 42.98B |
| Operating Income | 20.46B |
| Pretax Income | 16.42B |
| Net Income | 14.39B |
| EBITDA | 24.92B |
| EBIT | 20.46B |
| Earnings Per Share (EPS) | $7.30 |
Balance Sheet
The company has $9.67 billion in cash and $32.02 billion in debt, giving a net cash position of -$22.35 billion or -$11.65 per share.
| Cash & Cash Equivalents | 9.67B |
| Total Debt | 32.02B |
| Net Cash | -22.35B |
| Net Cash Per Share | -$11.65 |
| Equity (Book Value) | 44.75B |
| Book Value Per Share | 23.10 |
| Working Capital | -3.80B |
Cash Flow
In the last 12 months, operating cash flow was $21.07 billion and capital expenditures -$1.50 billion, giving a free cash flow of $19.58 billion.
| Operating Cash Flow | 21.07B |
| Capital Expenditures | -1.50B |
| Free Cash Flow | 19.58B |
| FCF Per Share | $10.20 |
Margins
Gross margin is 76.25%, with operating and profit margins of 36.29% and 25.53%.
| Gross Margin | 76.25% |
| Operating Margin | 36.29% |
| Pretax Margin | 29.13% |
| Profit Margin | 25.53% |
| EBITDA Margin | 44.21% |
| EBIT Margin | 36.29% |
| FCF Margin | 34.73% |
Dividends & Yields
This stock pays an annual dividend of $2.60, which amounts to a dividend yield of 2.07%.
| Dividend Per Share | $2.60 |
| Dividend Yield | 2.07% |
| Dividend Growth (YoY) | 6.80% |
| Years of Dividend Growth | 5 |
| Payout Ratio | 35.57% |
| Buyback Yield | 3.84% |
| Shareholder Yield | 5.91% |
| Earnings Yield | 5.99% |
| FCF Yield | 8.15% |
Analyst Forecast
The average price target for Novartis AG is $119.00, which is -5.18% lower than the current price. The consensus rating is "Hold".
| Price Target | $119.00 |
| Price Target Difference | -5.18% |
| Analyst Consensus | Hold |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | 4.70% |
| EPS Growth Forecast (5Y) | 14.36% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on May 11, 2000. It was a forward split with a ratio of 2:1.
| Last Split Date | May 11, 2000 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
Novartis AG has an Altman Z-Score of 3.8 and a Piotroski F-Score of 7.
| Altman Z-Score | 3.8 |
| Piotroski F-Score | 7 |